Jeffrey Church
Director of Finance/CFO chez IMUNON, INC.
Fortune : 5 932 $ au 31/03/2024
Profil
Jeffrey Wayne Church's current job is as the Chief Financial Officer, Secretary & Executive VP at Imunon, Inc. Mr. Church's former jobs include being the Chief Financial Officer & Executive Vice President at Dominari Holdings, Inc., the Chief Financial Officer, Secretary, Treasurer & VP at Novavax, Inc. from 2006 to 2007, the Chief Financial Officer at Meridian Medical Technologies LLC from 1986 to 1996, the Chief Financial Officer, Secretary & Treasurer at GenVec, Inc. from 1998 to 2006, and the Chief Financial Officer & Secretary at Alba Therapeutics Corp.
from 2007 to 2010.
Mr. Church obtained his undergraduate degree from the University of Maryland.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMUNON, INC.
0,04% | 26/03/2024 | 3 617 ( 0,04% ) | 5 932 $ | 31/03/2024 |
Postes actifs de Jeffrey Church
| Sociétés | Poste | Début |
|---|---|---|
| IMUNON, INC. | Director of Finance/CFO | 08/07/2010 |
Anciens postes connus de Jeffrey Church
| Sociétés | Poste | Fin |
|---|---|---|
Alba Therapeutics Corp.
 Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Director of Finance/CFO | 01/01/2010 |
| NOVAVAX, INC. | Director of Finance/CFO | 20/04/2007 |
| GENVEC INC | Director of Finance/CFO | 15/08/2006 |
Meridian Medical Technologies LLC
 Meridian Medical Technologies LLC Medical SpecialtiesHealth Technology Meridian Medical Technologies LLC develops auto injectors for the pharmaceutical and biotechnological industries. Its product Antidote Treatment Nerve Agent, Auto-Injector is intended as an initial treatment of the symptoms of organophosphorous nerve agent poisoning; additional medical care should be sought as soon as possible. The company was founded in 1968 and is headquartered in Columbia, MD. | Director of Finance/CFO | 01/01/1996 |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Comptroller/Controller/Auditor | - |
Formation de Jeffrey Church
| University of Maryland | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| DOMINARI HOLDINGS INC. | Health Technology |
| NOVAVAX, INC. | Health Technology |
| IMUNON, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Meridian Medical Technologies LLC
Meridian Medical Technologies LLC Medical SpecialtiesHealth Technology Meridian Medical Technologies LLC develops auto injectors for the pharmaceutical and biotechnological industries. Its product Antidote Treatment Nerve Agent, Auto-Injector is intended as an initial treatment of the symptoms of organophosphorous nerve agent poisoning; additional medical care should be sought as soon as possible. The company was founded in 1968 and is headquartered in Columbia, MD. | Health Technology |
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Health Technology |
